LIGAND PHARMACEUTICALS INC (LGND): debt financing — Ligand Pharmaceuticals extends credit facility maturity to Sept 2028, sets minimum EBITDA at $55M

LIGAND PHARMACEUTICALS INC

Third Amendment to Credit Agreement dated Sep 12, 2025 extends maturity to September 12, 2028.
New minimum consolidated EBITDA covenant: not less than $55 million for trailing four-quarter periods.
Amendment modifies credit agreement originally dated Oct 12, 2023, with all Lenders consenting.
Borrower reaffirmed obligations and Guarantors reaffirmed guarantees under the agreement.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

LIGAND PHARMACEUTICALS INC amended credit facility with Citibank, N.A. maturing September 12, 2028.

Instrument: credit facility
Counterparty: Citibank, N.A.
Maturity: September 12, 2028
Event: amendment

Exact text from the filing

to, among other things, extend the maturity date to September 12, 2028 and modify the minimum consolidated EBITDA

View on SEC.gov

Browse all debt financings →

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-205147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.